Anti-PD-L1 antibody [SP142] - C-terminal,Abcam,AB228462

Anti-PD-L1 antibody [SP142] - C-terminal (ab228462) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in ICC/IF, IHC-P and mIHC. Anti-PD-L1 antibody [SP142] - C-terminal (ab228462) was first used in a scientific publication in 2016 and has been cited over 95 times in peer reviewed journals. It's performance in IHC in human and mouse samples is trusted by the scientific community. Abcam's high quality manufacturing and validation processes ensure Anti-PD-L1 antibody [SP142] - C-terminal (ab228462) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. Anti-PD-L1 antibody [SP142] - C-terminal (ab228462) specifically detects PD-L1 (UniProt ID: Q9NZQ7; Molecular weight: 32kDa) and is sold in a convenient trial size to enable initial testing (20 µL) and larger sizes for subsequent scaling up experiments (100 µL, 500 µL and 1 mL). Conjugation-ready, carrier free format available for antibody clone SP142 - ab236238 . Antibody clone SP142 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor ® 647, Alexa Fluor ® 488, Alexa Fluor ® 594, Alexa Fluor ® 568, Alexa Fluor ® 555, Alexa Fluor ® 750 ( ab267563 , ab310995 , ab311750 , ab313030 , ab313231 , ab321463 ). Anti-PD-L1 antibody [SP142] - C-terminal (ab228462) is a clone from the portfolio of Spring Bioscience (Roche) SP clones which have been optimised for immunohistochemistry (IHC). PD-L1 allows tumors to escape immune detection by binding to the PD-1 receptor on T-cells, suppressing their function. Blocking this interaction with immune checkpoint inhibitors reactivates T-cells, enabling them to attack cancer cells. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Host

Rabbit

Reactivity

Human

Application

mIHC, ICC/IF, IHC-P

Platform ID

BAB667568822

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAnti-PD-L1 antibody [SP142] - C-terminal
Cat. No.AB228462
HostRabbit
IsotypeIgG
ReactivityHuman
ApplicationmIHC, ICC/IF, IHC-P
ClonalityMonoclonal
Clone NumberSP142
Concentration0.052 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A/G
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.6 Preservative: 0.1% Sodium azide Constituents: PBS, 1% BSA
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Plays a critical role in induction and maintenance of immune tolerance to self (PubMed : 11015443, PubMed : 28813410, PubMed : 28813417, PubMed : 31399419). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed : 11015443, PubMed : 28813410, PubMed : 28813417, PubMed : 36727298). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed : 10581077). Can also act as a transcription coactivator : in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis (PubMed : 32929201).. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed : 28813410, PubMed : 28813417). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity). See full target information CD274

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.